Research programme: therapeutics for bone disorders therapeutics - Scil Technology
Alternative Names: Research programme: orthopaedic therpaeutics - Scil Technology; ST 01Latest Information Update: 04 Nov 2017
Price :
$50 *
At a glance
- Originator Scil Technology
- Class Bone morphogenetic proteins
- Mechanism of Action Intercellular signalling peptide and protein stimulants; Osteogenesis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Bone disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Bone-disorders in Germany (Intraspinal, Implant)
- 31 Mar 2011 Preclinical development is ongoing in Germany
- 25 May 2005 Compounds in this programme are available for licensing (http://www.scil.com)